Estimates Revisions Genfit S.A. OTC Markets
Stocks
GNFT
US3722791098
Biotechnology & Medical Research
|
Delayed
OTC Markets
13:01:13 2026-03-09 EDT
|
5-day change | 1st Jan Change | ||
| 8.950 USD | +4.07% |
|
-.--% | +44.59% |
| 09-15 | French and Benelux stocks-Factors to watch on September 15 | RE |
| 09-15 | France's Genfit Plans Phase 2a Trial of Liver Failure Treatment | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Data source:
GENFIT(GNFT)
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Data source:
GENFIT(GNFT)
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
Data source:
GENFIT(GNFT)
EBIT
Dividend / Share (DPS)
Data source:
GENFIT(GNFT)
Cash or Net Debt
- Stock Market
- Stocks
- GNFT Stock
- GNFT Stock
- Consensus Genfit S.A.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
